A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Sponsor
Hunan Cancer Hospital
Study ID
NCT04974827
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    200mg/3weeks
  • Cisplatin or Carboplatin — DRUG
    Cisplatin (40mg/m²), every week Carboplatin(AUC 2)

Study Details

In this single-arm study, patient with cervical cancer who had recurrence of the pelvic wall after surgery ± Abdominal aortic lymph node metastasis will be included to evaluate the efficacy and safety of camrelizumab combined with concurrent chemoradiation and subsequent maintenance therapy

Key Dates

Start date
May 20, 2021
Status verified
Jul 2021
Primary completion
May 20, 2023
Completion
May 20, 2023

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab , Cisplatin or Carboplatin
    Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 5 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.

Primary Outcome Measure

Complete remission rate (CR) [ Time Frame: immediately after the concurrent chemoradiation ]

Central Contacts

Related Studies